SCHEMBL26106838

SCHEMBL26106838

CC(=O)c1cc(Cl)nc2c1ccn2C

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ AHR P35869 1/20 0.39
▸ KDM4E B2RXH2 1/20 0.36
▸ USP2 O75604 1/20 0.35
▸ HTT P42858 1/20 0.35
▸ GAA P10253 2/20 0.35
▸ KMT2A Q03164 2/20 0.35
▸ MEN1 O00255 1/20 0.35
▸ CYP1A2 P05177 1/20 0.35
▸ CYP3A4 P08684 1/20 0.35
▸ CYP2D6 P10635 1/20 0.35
▸ CYP2C19 P33261 1/20 0.35
▸ SMN1; SMN2 Q16637 2/20 0.34
▸ BRD4 O60885 2/20 0.34
▸ L3MBTL1 Q9Y468 1/20 0.34
▸ NOTUM Q6P988 1/20 0.34
▸ HSD17B10 Q99714 1/20 0.33
▸ PDK1 Q15118 1/20 0.33
▸ PDK2 Q15119 1/20 0.33
▸ PDK3 Q15120 1/20 0.33
▸ PDK4 Q16654 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30612050 1.00 AHR (0.39) AHRKDM4EUSP2HTTGAA
SCHEMBL31347270 0.88 KDM4E (0.40) KDM4EUSP2HTTGAAKMT2A
SCHEMBL26105200 0.88 KDM4E (0.40) KDM4EUSP2HTTGAAKMT2A
SCHEMBL30612180 0.84 KDM4E (0.56) KDM4EUSP2GAAKMT2AMEN1
SCHEMBL26106242 0.84 KDM4E (0.56) KDM4EUSP2GAAKMT2AMEN1
SCHEMBL30612107 0.80 POLB (0.41) KDM4EUSP2HTTKMT2AMEN1
SCHEMBL26107364 0.80 POLB (0.41) KDM4EUSP2HTTKMT2AMEN1
SCHEMBL29697245 0.76 HRH4 (0.36) MAPT
SCHEMBL22024527 0.76 HRH4 (0.36) MAPT
SCHEMBL30503534 0.75 KDM4E (0.41) KDM4EHTTGAAKMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4499629-A1 BICYCLIC HETEROARYL-CONTAINING COMPOUNDS AS IKZF2 DEGRADERS Oncopia Therapeutics, Inc. D/B/A SK Life Science Labs (US) 2025-02-05 — — EP disclosed
WO-2023183919-A1 BICYCLIC HETEROARYL-CONTAINING COMPOUNDS AS IKZF2 DEGRADERS ONCOPIA THERAPEUTICS, INC. D/B/A PROTEOVANT THERAPEUTICS, INC. (US) 2023-09-28 — — WO disclosed
Send feedback